Allarity Therapeutics, Inc. (ALLR) - Dilution Analysis

10-Q filing | 16.0M shares outstanding

10-K filing | 16.1M shares outstanding

S-3 filing: Allarity Therapeutics, Inc. is filing an S-3 to register a shelf offering of common stock, preferred stock, and debt securities, with a total proposed amount of $50,000,000.

10-Q filing | 14.7M shares outstanding

S-3 filing: This S-3 filing from Allarity Therapeutics, Inc. relates to the resale of up to 1,562,500 shares of common stock by a selling stockholder.

10-Q filing | 15.5M shares outstanding

RW filing: The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates and is requesting withdrawal of the Registration Statement.

10-Q filing | 17.0M shares outstanding

10-K filing | 7.3M shares outstanding

10-Q filing | 2.8M shares outstanding

S-3 filing: This S-3 filing registers 18,529,000 shares of common stock for resale by selling stockholders, issuable upon conversion of Series A Convertible Redeemable Preferred Stock.

8-K filing: Allarity Therapeutics, Inc. entered into a Securities Purchase Agreement to issue and sell 35,000 shares of Series A Convertible Redeemable Preferred Stock at $90 per share, for gross proceeds of approximately $3.15 million, and plans to hold a stockholder meeting to consider a reverse stock split. ($3.15M proceeds)

10-Q filing | 42.4M shares outstanding

10-Q filing | 17.6M shares outstanding

RW filing: The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates and is withdrawing the Registration Statement.

S-1/A filing: Allarity Therapeutics, Inc. is offering 5,000,000 shares of its common stock at an assumed public offering price of $2.00 per share.

8-K filing: Stock split 1-for-20 | Outstanding: 6,178,892 → 308,944

S-1/A filing: This S-1/A filing, dated April 5, 2024, relates to an offering of up to 26,569,246 shares of common stock, warrants, and pre-funded warrants for a total of $8 million subject to completion.

10-K filing | 6.2M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of common stock, Series A Common Warrants, and Series B Common Warrants with the intention to use the net proceeds to make payments under the Novartis license agreement, to continue clinical trials, to pay account payables and accrued liabilities outstanding, and for working capital and general corporate purposes.

S-1/A filing: Allarity is offering up to 13,333,333 shares of common stock, Series A Common Warrants, Series B Common Warrants, and Pre-Funded Warrants at a public offering price of $0.60 per share.

S-1/A filing: This S-1/A filing describes an offering of up to 13,333,333 shares of common stock, common warrants, and pre-funded warrants with the net proceeds to be used for payments under the Novartis license agreement, to continue our clinical trials, to pay account payables and accrued liabilities outstanding, and for working capital and general corporate purposes.

10-Q filing | 4.6M shares outstanding

S-3 filing: The company filed an S-3 form to register a shelf offering of up to $50,000,000 of common stock, preferred stock, warrants, debt securities, and units.

S-1 filing: Allarity is filing an S-1 to offer common stock, common warrants, and pre-funded warrants to raise capital for payments under the Novartis license agreement, to continue clinical trials, to pay account payables and accrued liabilities, and for working capital and general corporate purposes.

S-3/A filing: This prospectus relates to the resale of the Inducement Warrant Shares issuable upon exercise of the Inducement Warrants by the September Investors.

S-3 filing: This prospectus relates to the resale of the Inducement Warrant Shares issuable upon exercise of the Inducement Warrants by the September Investors.

8-K filing: Allarity Therapeutics entered into an inducement offer letter agreement with two warrant holders to reduce the exercise price of existing warrants to $1.00, and those holders will receive new warrants to purchase additional shares of common stock at the same exercise price. ($2.54M proceeds)

10-Q filing | 2.7M shares outstanding

8-K filing: Allarity Therapeutics, Inc. completed a public offering on July 10, 2023, selling shares of common stock, pre-funded warrants, and common warrants for gross proceeds of approximately $11 million. ($11.0M proceeds)

8-K filing: Allarity Therapeutics, Inc. entered into a Secured Note Purchase Agreement with 3i LP, issuing a secured promissory note for $350,000, and potentially 486 shares of Series A Convertible Preferred Stock upon conversion.

S-1/A filing: This is an S-1/A filing for a proposed offering of common stock, common warrants, and pre-funded warrants.

8-K filing: Stock split 1-for-40 | Outstanding: 20,142,633 → 503,566

S-1 filing: This is an S-1 filing for an offering of common stock, common warrants and pre-funded warrants.

8-K filing: Allarity Therapeutics, Inc. entered into a Fourth Amendment to the Exclusive License Agreement with Eisai, Inc. to postpone an extension payment, restructure the payment schedule, and extend the deadline to complete enrollment in a clinical trial. They also amended the voting provisions of the Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock in relation to a reverse stock split proposal.

10-Q filing | 19.1M shares outstanding

8-K filing: Allarity Therapeutics, Inc. reports 15,530,763 shares of common stock outstanding as of April 28, 2023, resulting from the issuance of 2,869,330 shares of common stock upon the closing of a public offering on April 21, 2023, exercise of pre-funded warrants, and conversion of Series A Convertible Preferred Stock.

8-K filing: Allarity Therapeutics, Inc. sold 2,869,330 shares of common stock, pre-funded warrants to purchase up to 7,130,670 shares of common stock, and common warrants to purchase up to 10,000,000 shares of common stock at a combined purchase price of $0.75 per share and related Common Warrant, for aggregate gross proceeds of approximately $7.5 million in a public offering that closed on April 21, 2023. ($7.5M proceeds)

S-1/A filing: This S-1/A filing includes an offering of up to 13,888,888 shares of common stock and common warrants to purchase up to 13,888,888 shares of common stock, as well as pre-funded warrants for certain purchasers.

8-K filing: Allarity Therapeutics, Inc. entered into a First Amendment to the Secured Note Purchase Agreement with 3i, LP, providing for additional note purchases and amending the security agreement to provide security interest for the additional notes.

S-1/A filing: This S-1/A filing details an offering of common stock, common warrants, and pre-funded warrants with the aim to raise $20,000,000 for clinical trials, working capital, and general corporate purposes.

S-1/A filing: This S-1/A filing relates to an offering of common stock, common warrants, and pre-funded warrants. The company intends to use the net proceeds from this offering of $10,000,000 (assuming a combined public offering price of $2.57, based on the closing sale price of our common stock on the Nasdaq Global Market on March 27, 2023) to initiate our clinical trial, and for working capital and general corporate purposes.

8-K filing: Stock split 1-for-35 | Outstanding: 30,000,000 → 979,846

S-1 filing: The filing is an S-1 form related to an offering of common stock, common warrants, and pre-funded warrants.

10-K filing | 30.0M shares outstanding

8-K filing: Allarity Therapeutics, Inc. entered into a Securities Purchase Agreement with an accredited investor for the purchase and sale of 50,000 shares of Series C Convertible Redeemable Preferred Stock at $24.00 per share, for gross proceeds of $1.2 million, and the offering closed on February 28, 2023. ($1.2M proceeds)

8-K filing: As of January 13, 2023, the Company had 18,367,757 shares of common stock outstanding. Since December 2021, the Company has issued 10,291,933 shares of common stock as a result of exercise of conversions of 6,965 shares of Series A Preferred Stock.

8-K filing: The company entered into a Secured Note Purchase Agreement for $2,666,640 with 3i LP. They also amended Series A Convertible Preferred Stock and established Series B Preferred Stock to be distributed as a dividend to common and Series A shareholders.

10-Q filing | 9.9M shares outstanding

10-Q filing | 10.3M shares outstanding

8-K filing: Allarity Therapeutics, Inc. and 3i, LP amended the Forbearance Agreement and Waiver to extend the forbearance period date to June 20, 2022, with a possible extension to July 5, 2022, contingent on removing restrictions on 441,005 shares of common stock issued upon conversion of Series A Preferred Stock.

POS AM filing: This prospectus relates to the offer and sale from time to time of up to 13,426,181 shares of Common Stock consisting of shares issued upon conversion of Series A Preferred Stock, shares issuable upon exercise of the PIPE Warrant, and additional shares issuable upon conversion of Preferred Stock.

10-Q filing | 9.3M shares outstanding

10-K filing | 8.8M shares outstanding

8-K filing: The company filed a Certificate of Designations setting forth the rights, preferences, privileges and restrictions for 20,000 shares of Series A Convertible Preferred Stock.

S-1/A filing: This S-1/A filing registers up to 12,618,590 shares of common stock for resale by selling stockholders, including shares issuable upon conversion of preferred stock and exercise of warrants.

8-K filing: The company entered into employment agreements with Jens E. Knudsen, James Cullem, and Marie Foegh, providing for salary, bonus potential, and potential equity compensation in the form of incentive stock options for Mr. Knudsen subject to NASDAQ listing.

S-1/A filing: This S-1/A filing registers up to 12,618,590 shares of common stock for resale by selling stockholders, consisting of shares issuable upon conversion of Series A Preferred Stock and exercise of PIPE Warrants, with the company not receiving proceeds from the sale of these shares.

10-Q filing | 397.2M shares outstanding

S-1/A filing: This S-1/A filing relates to the offer and sale from time to time by 3i, LP, of up to 12,618,590 shares of Common Stock consisting of shares issued upon conversion of Series A Preferred Stock, shares issuable upon exercise of a PIPE Warrant, and additional shares issuable upon conversion of Preferred Stock.

S-1 filing: The filing relates to the offer and sale from time to time by the selling stockholders of up to 13,964,057 shares of Common Stock consisting of shares issued upon conversion of preferred stock, shares issuable upon exercise of a warrant, and additional shares issuable upon conversion of preferred stock.